Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,777.70up ₹16.70 (0.95%)BSE ₹1,778.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,761.00.
30 Oct: open ₹1,769.00, high ₹1,855.00, low ₹1,766.20
52-week range of traded prices to 30 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,26,530 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.90
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,30,21833.2% delivered
Sun Pharmaceutical Industries share news and announcements
1,451 announcements, routine notices left out, newest first. Page 27 of 30.
Jul 2009
29 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 78759 lacs for quarter ending on 30-JUN-2009 against Rs. 104177 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 16384 lacs for the quarter ending on 30-JUN-2009 against Rs. 50145 lacs for the quarter ending on 30-JUN-2008.29 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 40588 lacs for quarter ending on 30-JUN-2009 against Rs. 67081 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12151 lacs for the quarter ending on 30-JUN-2009 against Rs. 28078 lacs for the quarter ending on 30-JUN-2008.14 Jul · Business
Press release dated July 14, 2009, titled "Sun Pharma to announce Q1 2009-10 results on July 29, 2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”10 Jul · Business
Press release dated July 10, 2009, titled "Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jul · Business
Press release dated July 07, 2009, titled "Sun Pharma announces USFDA approval for generic Casodex (R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Business
Press release dated July 02, 2009, titled "Sun Pharma Industries Ltd announces USFDA tentative approval for generic Optivar". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
26 Jun · Business
Press release dated June 26, 2009, titled "Sun Pharma to host conference call". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jun · Business
Press release dated June 19, 2009, titled "Sun Pharma announces USFDA approval for generic Accupril tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
30 May · Business
Press release dated May 30, 2009, titled "Sun Pharma reports Q4 and FY09 financials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 May · Corporate action
Register of Members and Share Transfer Books of the Company will be closed from August 25, 2009 to September 05, 2009 (both days inclusive) for the purpose of payment of dividend.30 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2009 has recommended payment of dividend of Rs. 13.75 per equity share of Rs.5/- each of the Company for the year ended March 31, 2009 subject to the approval of the members at the ensuing Annual General Meeting of the Company.30 May · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 427230 lacs for year ending on 31-MAR-2009 against Rs. 335653 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 181773 lacs for the year ending on 31-MAR-2009 against Rs. 148690 lacs for the year ending on 31-MAR-2008.30 May · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 276975 lacs for year ending on 31-MAR-2009 against Rs. 236564 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 126529 lacs for the year ending on 31-MAR-2009 against Rs. 101404 lacs for the year ending on 31-MAR-2008.29 May · Updates
Sun Pharmaceuticals Industries Ltd had informed the Exchange regarding a press release titled "Sun Pharma to announce Q4 and FY 2008-09 results on May 30, 2009". The Company has now informed the Exchange that: "Our analyst earnings call for Q4 2008-09 is now rescheduled to 8 am on June 1, 2009".19 May · Updates
"Sun Pharma to announce Q4 and FY 2008-09 results on May 30, 2009". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 May · Board meeting
Interalia, (1) To consider the audited financial results of the Company for the year ended March 31, 2009. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2009 subject to the approval of the shareholders at the ensuing Annual General Meeting.7 May · Business
Press release dated May 07, 2009, titled "Sun Pharma announces USFDA tentative approval for generic Uroxatral Extended Release (R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
21 Apr · Results
The Company shall be publishing the Audited Annual Accounts/Results for the year ended 31st March, 2009 within the stipulated time period of three months from the closure of the financial year i.e. by 30th June, 2009. Accordingly, the un-audited financial results for the fourth quarter / year ended 31st March, 2009 will not be published by the Company13 Apr · Business
Press release dated April 13, 2009, titled "Sun Pharma announces USFDA approval to market generic Roxicodone tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Apr · Updates
Our subsidiary, Alkaloida Chemical Company Exclusive Group Ltd has extended the Expiration Date of the Tender Offer for purchase of all outstanding ordinary shares of Taro Pharmaceutical Industries Ltd, Israel to 5:00 p.m. , New York City time, on Friday, April 17, 2009. If the Temporary Order of the Supreme Court of Israel remains in effect on April 17, 2009, the Offer will be further extended. The Offer had previously been scheduled to expire at 5:00 p.m. New York City time, on Friday, April 3, 2009". Further, the Company has informed that " Company is filing necessary notification to the U.S. Securities and Exchange Commission informing them about this extension under required format
Mar 2009
31 Mar · Updates
Vides its letter dated March 30, 2009 that : "The Supreme Court of Israel that although all the parties to the STO Litigation, as well as the Levitt and Moros families, engaged in a mediation process, as previously recommended by the Supreme Court of Israel, to resolve the dispute over the STO Litigation in respect of our takeover of Taro Pharmaceutical Industries Ltd, such meditation attempts were unsucessful and no agreement was reached. We are now awaiting a decision of the Supreme Court of Israel." Further, "The Company is filling necessary notification to the Securities and Exchange Commission informing them about this under required format".30 Mar · Business
Press release dated March 28, 2009, titled "Sun Pharma announces USFDA approval to market generic Topamax (R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Mar · Business
Press release dated March 06, 2009, titled "Sun Pharmaceutical Extends Tender Offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
11 Feb · Disclosure
Disclosure pursuant to Regulation 8A(4) of the SEBI Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2009, in respect of the details of the shares pledged by the promoter or persons forming part of the promoter group. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
30 Jan · Business
Press release dated January 30, 2009, titled "Sun Pharma reports continuing growth in Q3; Net sales up 14%, Net profit up 28%, one more site approved by USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 63106 lacs for quarter ending on 31-DEC-2008 against Rs. 73391 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 25668 lacs for the quarter ending on 31-DEC-2008 against Rs. 34593 lacs for the quarter ending on 31-DEC-2007.30 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 91827 lacs for quarter ending on 31-DEC-2008 against Rs. 80397 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 40864 lacs for the quarter ending on 31-DEC-2008 against Rs. 33647 lacs for the quarter ending on 31-DEC-2007.29 Jan · Business
Press release dated January 29, 2009, titled "Sun Pharmaceutical extends tender offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jan · Business
Press release dated January 24, 2009, titled "Sun Pharma to announce Q3 2008-09 results on January 30, 2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Board meeting
Meeting on 30 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”8 Jan · Business
Press release dated January 07, 2009, titled "Sun Pharmaceutical Extends Tender offer for Taro." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jan · Business
Press release dated January 07, 2009, titled "Sun Pharma receives USFDA approvals for 4 generic products- Company receives its first controlled substance product approval." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jan · Updates
Letter sent to Dr. Barrie Levitt, Taro Pharmaceutical Industries Ltd regarding Settlement Proposals to resolve the dispute over the Special Tender Offer Litigation. A copy of the said letter shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jan · Updates
"We have sent two letters to Taro Pharmaceutical Industries Ltd (Taro) on 2nd January, 2009 as shown below: 1) One letter to the Board of Directors of Taro reiterating settlement proposals communicated on December 22, 2008 by Sun Pharma's Israeli legal counsel to the Taro's Israeli legal counsel, in accordance with the suggestion of the Supreme Court of Israel that the parties negotiate with one another to reach a settlement to resolve the dispute over the Special Tender Offer Litigation. 2) Another letter to the Chairman of the Audit Committee of Taro highlighting concerns on the financial statements as depicted in the Form 6-K filed with Securities and Exchange Commission (SEC), USA by Taro". Further, Company has informed that the company has also filed necessary notification with respect of the above to the SEC. The copies of the said letters shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
19 Dec · Business
Press release dated December 19, 2008, titled "Sun Pharmaceutical Extends tender offer for Taro." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
28 Nov · Business
Press release dated November 27, 2008, titled "Sun Pharma update on ANDA for generic Effexor XR". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Nov · Business
Press release dated November 25, 2008, titled "Sun Pharma Augments Presence in Controlled Substances". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Nov · Business
Press release dated November 07, 2008, titled "Sun Pharmaceutical Extends Tender Offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Nov · Business
Press release dated November 05, 2008, titled "Sun Pharmaceutical announces USFDA approval to market generic Sinemet(R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
25 Oct · Business
Press release dated October 25, 2008, titled "Sun Pharmaceutical continues strong performance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 221961 lacs for half year ending on 30-SEP-2008 against Rs. 129539 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 101421 lacs for the half year ending on 30-SEP-2008 against Rs. 47196 lacs for the half year ending on 30-SEP-2007.25 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 117784 lacs for quarter ending on 30-SEP-2008 against Rs. 66790 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 51277 lacs for the quarter ending on 30-SEP-2008 against Rs. 22894 lacs for the quarter ending on 30-SEP-2007.25 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 136834 lacs for half year ending on 30-SEP-2008 against Rs. 105009 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 58392 lacs for the half year ending on 30-SEP-2008 against Rs. 42022 lacs for the half year ending on 30-SEP-2007.25 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 69753 lacs for quarter ending on 30-SEP-2008 against Rs. 54128 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 30314 lacs for the quarter ending on 30-SEP-2008 against Rs. 19483 lacs for the quarter ending on 30-SEP-2007.15 Oct · Business
Press release dated October 15, 2008, titled "Sun Pharma to announce Q2 and H1 2008-09 results on Oct. 25, 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Oct · Board meeting
Interalia, to consider and take on record the unaudited financial results of the Company for the half year / second quarter ended September 30, 2008.3 Oct · Business
Press release dated October 03, 2008, titled "Sun Pharmaceutical Extends Tender Offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
24 Sep · Business
Press release dated September 23, 2008, titled " Sun Pharmaceutical announces USFDA approval to market generic Paraplatin(R) injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Sep · Change in shareholding
Sun Pharmaceuticals Industries Ltd has submitted revised shareholding pattern for the quarter ended June 30, 2008. Further the Company has informed the Exchange that there was error under clause 1(a) of category A i.e. Shareholding of promoter and promoter group for Individuals / Hindu Undivided Family wherein we have mentioned the total no of shares as 30534982 instead of 30531532 and in respect of Mr. Jayant Shantilal Sanghvi, the total no of shares was wrongly mentioned as 876634 instead of 873184 shares. A copy of the Revised Shareholding Pattern shall be available on the NSE website.